Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcus Biosciences (RCUS) Preferred Stock Liabilities (2017)

Arcus Biosciences (RCUS) has 1 years of Preferred Stock Liabilities data on record, last reported at $226.2 million in Q4 2017.

  • For Q4 2017, Preferred Stock Liabilities changed N/A year-over-year to $226.2 million; the TTM value through Dec 2017 reached $226.2 million, changed N/A, while the annual FY2017 figure was $226.2 million, N/A changed from the prior year.
  • Preferred Stock Liabilities reached $226.2 million in Q4 2017 per RCUS's latest filing.
  • Across five years, Preferred Stock Liabilities topped out at $226.2 million in Q4 2017 and bottomed at $226.2 million in Q4 2017.